Biogen IDEC Rated Buy and 2 More Healthcare Stocks at 52-Week Highs
Biogen IDEC (NASDAQ:BIIB): Closing price $207.01
TheStreet Ratings has Biogen Idec shares at Buy, as “The firm’s strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.” Shares closed up 3.37 percent on Friday at $207.01, and have been traded in a 52-week range of $124.23 to $209.00.
BioMarin Pharmaceutical (NASDAQ:BMRN): Closing price $64.71
Chief Executive Jean-Jacques Bienaime will host a conference call and webcast on April 25th, at 5:00 p.m. Eastern Time to discuss his firm’s first quarter 2013 financial results. Shares closed up 1.62 percent on the day at $64.71, having been traded between $32.20 and $64.95 the last 52 weeks.
Amgen (NASDAQ:AMGN): Closing price $111.57
Amgen is a biotechnology medicines firm which engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases mostly in the United States, Europe, and Canada. The company has a market cap of $81.1 billion. Shares closed up 3.10 percent on Friday at $111.57, and have been traded in a 52-week range of $65.37 to $112.10.